Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 10, 2008. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary shares by seven individuals under the Company's Share Reward Plan on July 9, 2008. The shares were purchased at a price of £12.32 per Ordinary share. Each individual acquired 10 shares through a personal contribution (partnership element) and 10 shares through a company contribution (matching element).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share transactions described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 9, 2008.
- Share Price: £12.32 per Ordinary share.
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr D Learmouth, Mr D S Redfern, and Ms C Thomas.
- Volume per Person: 20 Ordinary shares total (10 personal, 10 company match).
- Plan Details: Transactions executed under the Share Reward Plan entered into on October 5, 2001.